Brentley Smith, MD
Gynecologic Oncology · Marietta, GANPI 1841633757
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.5%), consulting fees and education — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Pfizer at 40.2% of the total. Reporting peaked in 2024 at $2,819 and has fallen 76.1% since, to $674 in 2025.
Across 127 payments — averaging $42.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- GSK$611
- AstraZeneca$596
- Merck$480
- Seagen Inc.$352
- LSI Solutions Inc$204
- plus $976 from 24 others
What the payments were for
- Consulting fees$2,16040%
- Food & beverage$3,20160%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 1 | $2,160 |
| GSK | 24 | $611 |
| AstraZeneca | 24 | $596 |
| Merck | 20 | $480 |
| Seagen Inc. | 17 | $352 |
| LSI Solutions Inc | 3 | $204 |
| Eisai Inc. | 8 | $179 |
| Tesaro, Inc. | 1 | $125 |
| Intuitive Surgical | 1 | $77 |
| Clovis Oncology, Inc. | 4 | $73 |
| Myriad Genetic Laboratories, Inc. | 2 | $58 |
| Astellas Pharma US Inc | 2 | $44 |
| Smith+Nephew | 2 | $44 |
| Fennec Pharmaceuticals, Inc. | 2 | $43 |
| On Target Laboratories, Inc | 1 | $31 |
| Medtronic | 1 | $30 |
| AbbVie | 1 | $29 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Abbott | 1 | $24 |
| Aspira Women's Health Inc | 1 | $24 |
| Immunogen, Inc. | 1 | $22 |
| Caris MPI, Inc. | 1 | $21 |
| Novartis | 1 | $21 |
| Davol Inc. | 1 | $20 |
| Solventum Corporation | 1 | $17 |
| Mimedx Group, Inc. | 1 | $16 |
| Baxter Healthcare | 1 | $15 |
| Boston Scientific | 1 | $14 |
| Cardinal Health 414 LLC | 1 | $13 |
| Aroa Biosurgery Incorporated | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,379 in reported general payments places this provider in the 65th percentile of 49 gynecologic oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 12 | $6,692 |
| Estradiol | 24 | $965 |
| Ondansetron Hcl | 58 | $850 |
| Gabapentin | 75 | $771 |
| Prochlorperazine Maleate | 48 | $523 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 58 | $481 |
| Oxycodone Hcl | 112 | $421 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 19 | $248 |
| Duloxetine Hcl | 19 | $232 |
| Ibuprofen | 59 | $144 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 18 | $84 |
| Ondansetron OdtOndansetron | 12 | $54 |
| Zolpidem Tartrate | 13 | $38 |
| Tramadol Hcl | 24 | $36 |
| Letrozole | 12 | $34 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $2,160 | $6,69212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 49 gynecologic oncology providers in Georgia.
Other gynecologic oncology in Marietta
- Amy CarrollMarietta$5K
- James BurkeSavannah$276K
- Benedict BenignoAtlanta$273K
- Sharad GhamandeAugusta$214K
- Ruchi GargNewnan$125K
- Adam PyrzakAtlanta$116K
- Gerald FeuerAtlanta$102K
- Margarett EllisonMoultrie$81K
- Vijaya GalicGainesville$35K
- Guilherme CantuariaAtlanta$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.